by
Gus Iversen, Editor in Chief | July 24, 2026
The Chicago-based Tempus AI has agreed to acquire molecular diagnostics company Personalis in a transaction valued at approximately $1.5 billion, a move that expands Tempus' presence in molecular residual disease (MRD) testing and cancer monitoring.
The acquisition builds on a partnership established in 2023, when Tempus invested in Personalis and began commercializing the company's NeXT Personal MRD test. Following the transaction, Tempus plans to integrate Personalis' tumor-informed MRD technology with its AI-enabled precision oncology platform and multimodal clinical and molecular data assets.
MRD testing detects small amounts of circulating tumor DNA that remain after treatment and can be used to monitor treatment response or identify cancer recurrence. Personalis said its NeXT Personal assay has Medicare coverage in three clinical indications.
Ad Statistics
Times Displayed: 26678
Times Visited: 69 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
"MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs," Tempus CEO Eric Lefkofsky said in a statement.
Personalis CEO Chris Hall said the acquisition would provide the company with additional scale and resources while expanding access to its testing platform.
Under the terms of the agreement announced July 20, Personalis shareholders will receive $16.25 per share, representing a total enterprise value of $1.5 billion, net of Tempus' existing ownership stake. The transaction is structured primarily as a stock deal, although Tempus may elect to pay up to half of the consideration in cash. The acquisition has been approved by both companies' board of directors and is expected to close in late 2026 or early 2027, subject to shareholder approval, regulatory clearance and other customary closing conditions.
Personalis also released preliminary second-quarter financial results, reporting revenue of $22.4 million. The company said it performed 10,384 clinical tests during the quarter, a 33% increase in testing volume compared with the previous quarter.
